Oh no, Ozempic! Eli Lilly’s New Weight-Loss Drug KOs Rival Treatments

Eli Lilly reported 68‑week Phase II results for retatrutide in 445 people with obesity and knee arthritis showing an average weight loss of 71.2 lb (28.7%) on a 12 mg weekly dose and meaningful reductions in knee pain, outperforming Lilly’s Zepbound (≈21% weight loss) and Novo Nordisk’s Wegovy (≈15%); BMO’s bull case even models ~25% average loss. The drug targets GLP‑1, GIP and glucagon, but tolerability is a material issue—43% reported nausea and ~18% discontinued the 12 mg dose—though Lilly says dropouts were concentrated among lower‑BMI patients and were 12% for BMI≥35, more in line with competitors. The data sharpens competitive pressure in the obesity market, underpinning Lilly’s strong share performance and $1 trillion valuation while exacerbating headwinds for Novo Nordisk, and will shape positioning toward higher‑BMI patients pending peer‑reviewed results and further safety analysis.

Analysis

Eli Lilly reported 68-week Phase II results for retatrutide in 445 people with obesity and knee arthritis showing an average weight loss of 71.2 lb (28.7%) on a 12 mg weekly dose, materially outperforming Lilly’s Zepbound (~21% average loss) and Novo Nordisk’s Wegovy (~15%); BMO’s bull case models ~25% average weight loss. The trial also recorded meaningful reductions in arthritis-related knee pain, underscoring potential symptomatic benefits beyond pure weight loss.

Tolerability is a significant constraint: 43% of patients reported nausea and roughly 18% discontinued the 12 mg dose, with JPMorgan noting tolerability is “somewhat worse vs. Zepbound.” Lilly states dropouts were concentrated among lower-BMI patients and were 12% for those with BMI ≥35, implying the company could initially position retatrutide for higher-BMI populations. Retatrutide’s mechanism targets GLP-1, GIP and glucagon, differentiating it pharmacologically from current competitors.

Market reaction has been pronounced—LLY shares are up over 30% in 2025 and Lilly reached a $1 trillion valuation—while Novo Nordisk’s Copenhagen-listed shares have fallen 48.7% amid slashed forecasts and intensifying competitive pressure. Key near-term determinants of commercial upside and risk are the peer-reviewed full data, larger Phase III safety/tolerability readouts, and whether elevated discontinuation rates persist or are confined to lower-BMI cohorts.

Key Decisions for Investors

• Consider adding modest, tactical exposure to LLY given the superior Phase II efficacy signal (28.7% mean weight loss) and strong market reaction, but cap position size until peer-reviewed data and Phase III tolerability/readouts mitigate safety risk
• Reduce or hedge exposure to NVO in the near term due to heightened competitive pressure and its 48.7% share decline unless Novo demonstrates clear advantages in tolerability, patient selection, or pricing
• Monitor upcoming catalysts closely—publication of full trial data, BMI‑stratified discontinuation rates, and Phase III results—as these will materially affect addressable market size and labeling; reassess positions when those data arrive
• Use protective sizing and hedges (e.g., options or stop-losses) around LLY exposure to guard against execution, regulatory or tolerability setbacks while waiting for confirmatory safety and larger-scale efficacy evidence